Drug Details

General Information of the Drug (ID: DR3651)
Name
Micafungin
Synonyms
Micafungin; Mycamine; 235114-32-6; UNII-R10H71BSWG; Micafungin [INN]; CHEBI:600520; R10H71BSWG; Micafungin (INN); Mycamine(TM); FK463; CHEMBL457547; SCHEMBL11893279; C56H71N9O23S; Pneumocandin A0, 1-((4R,5R)-4,5-dihydroxy-N2-(4-(5-(4-(pentyloxy)phenyl)-3-isoxazolyl)benzoyl]-L-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-L-threonine)-; BDBM50478216; DB01141; X7260; D08218; Z-3191; 114M326; J-015136; Q6827850; [5-[(1S,2S)-2-[[(1R)-3-amino-1-hydroxy-3-oxo-propyl]-tetrahydroxy-[(1R)-1-hydroxyethyl]-methyl-hexaoxo-[[4-[5-(4-pentoxyphenyl)isoxazol-3-yl]benzoyl]amino][?]yl]-1,2-dihydroxy-ethyl]-2-hydroxy-phenyl] hydrogen sulfate; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}
    Click to Show/Hide
Molecular Type
Small molecule
Disease Candidosis [ICD-11: 1F23] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.17 mL/min/kg
Elimination
1% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 14 - 17 hours
Metabolism
The drug is metabolized via the arylsulfatase with further metabolism to M-2 (methoxy form) by catechol-O-methyltransferase
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.3 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.0023%
Vd
The volume of distribution (Vd) of drug is 0.39 +/- 0.11 L/kg
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C56H71N9O23S
PubChem CID
477468
Canonical SMILES
CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O
InChI
1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1
InChIKey
PIEUQSKUWLMALL-YABMTYFHSA-N
CAS Number
CAS 235114-32-6
ChEBI ID
CHEBI:600520
TTD Drug ID
D06TOE
DrugBank ID
DB01141
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Farnesol      Mosla chinensis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Candida parapsilosis isolates Microorganism model Candida parapsilosis
Candida parapsilosis ATCC 22019 Microorganism model Candida parapsilosis
                    Experimental
                    Result(s)		 Caspofungin and micafungin in combination with farnesol showed synergistcant interaction against Candida parapsilosis biofilms.
Target and Pathway
Target(s) Fungal 1,3-beta-glucan synthase (Fung GSC2)  Molecule Info  [3]
KEGG Pathway Starch and sucrose metabolism Click to Show/Hide
2 MAPK signaling pathway - yeast
References
Reference 1 Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
Reference 2 Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms. Int J Antimicrob Agents. 2016 Apr;47(4):304-10.
Reference 3 An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74.
 Download Picture         KEGG Link